70
Views
3
CrossRef citations to date
0
Altmetric
Malignancy

Interleukin 4 (IL4), IL10 and IL13 Inhibit in vitro Cytokine Secretion by Acute Myelogenous Leukemia Blasts in the Presence of Exogenous Hematopoietic Growth Factors

Pages 443-450 | Received 22 Oct 1998, Published online: 13 Jul 2016

References

  • Puri R. K. (1995). Structure and function of interleukin 4 and its receptor. Cancer Treat. Res., 80, 143–185.
  • Benjamin, D. (1995). Interleukin 10 (IL10). Cancer Treat. Res., 80, 305–319.
  • McKenzie, A. N. J. and Zurawski, G. (1995). Interleukin 13: characterization and biological properties. Cancer Treat. Res., 80, 367–378.
  • Bruserud, Ø., Mentzoni, L., Bühring, H.-J. and Pawelec, G. (1996). Effects of hematopoietic growth factors on Interleukin 6 secretion by blast cells derived from acute myelogenous leukemia patients. Acta Haematol., 96, 155–161.
  • Bruserud, Ø., Nesthus, I., Bühring, H.-J. and Pawelec, G. (1995). Cytokine modulation of interleukin 1 and tumour necrosis factor α secretion from acute myelogenous leukaemia blast cells in vitro. Leukemia Res., 19, 15–22.
  • Bruserud, Ø., Gjertsen, B. T., Brustugun, O. T., Bassøe, C.-F., Nesthus, I., Akselsen, P. E., Bühring, H.-J. and Pawelec, G. (1995). Effect of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia, 9, 1910–1920.
  • Bruserud, Ø. (1996). Effects of interleukin 13 on cytokine secretion by human acute myelogenous leukemia blasts. Leukemia, 10, 1497–1503.
  • Jansen, J. H., Fibbe, W. E., Wientjens, G. J. H. M., van Damme, J., Landegent, J. E., Willemze, R. and Kluin-Nelemans, J. C. (1991). Interleukin 4 downregulates the expression of CD14 and the production of interleukin 6 in acute myeloid leukemia. Lymph. Cytokine Res., 10, 457–461.
  • Bruserud, Ø. (1998). Interleukin 4 (IL4), IL10 and IL13 in acute myelogenous leukemia. Cytokines Cell. Mol. Ther., 4, 187–198.
  • Akashi, K., Harada, M., Shibuya, T., Eto, T., Takamatsu, Y., Teshima, T. and Niho, Y. (1991). Effects of interleukin 4 and interleukin 6 on the proliferation of CD34+ and CD34− blasts from acute myelogenous leukemia. Blood, 78, 197–204.
  • Jansen, J. H., Fibbe, W. E., Wientjens, G. J. H. M., Willemze, R. and Kluin-Nelemans, J. C. (1993). Inhibitory effect of interleukin 4 on the proliferation of acute myeloid leukemia cells with myelomonocytic differentiation (AML-M4/M5); the role of interleukin 6. Leukemia, 7, 643–645.
  • Miyauchi, J., Clark, S. C., Tsunematsu, Y., Shimizu, K., Park, J.-W., Ogawa, T. and Toyama, K. (1991). Interleukin 4 as a growth regulator of clonogenic cells in acute myelogenous leukemia in suspension culture. Leukemia, 5, 108–115.
  • Wagteveld, A. J., Esselink, M. T., Limburg, P., Halie, M. R. and Vallenga, E. (1992). The effects of IL1β and IL4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. Leukemia, 6, 1020–1024.
  • Imai, Y., Tohda, S., Nagata, K., Suzuki, T., Nara, N. and Aoki, N. (1991). Effects of recombinant IL4 on the growth and differentiation of blast progenitors stimulated with G-CSF, GM-CSF and IL3 from acute myelogenous leukaemia patients. Br. J. Haematol., 78, 173–179.
  • Strunk, D. and Linkesch, W. (1997). Acute myelogenous leukemia cells can be differentiated into dendritic cells in vitro. Blood, 90, (suppl. 1), 188a.
  • Choudhury, A., Agusala, K., Suturia, S., Estey, E., Champlin, R. and Claxton, D. (1997). Leukemic dendritic cells derived in vitro from AML patients can stimulate antileukemic activity in autologous T cell populations. Blood, 90 (suppl. 1), 508a.
  • Dinarello, C. A. (1991). Interleukin 1 and interleukin 1 antagonism. Blood, 77, 1627–1652.
  • Vasalli, P. (1992). The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol., 10, 411–452.
  • Hirano, T. (1992). The biology of interleukin 6. Chem. Immunol., 51, 153–180.
  • Fiedler, W., Suciu, E., Wittlief, C., Ostertag, W. and Hossfeld, D. K. (1990). Mechanisms of growth factor expression in acute myeloid leukemia (AML). Leukemia, 4, 459–461.
  • McGlave, P. B., Haake, R. J., Bostrom, B. C., Brunning, R., Hurd, D. D., Kim, T. H., Nesbit, M. E., Vercellotti, G. M., Weisdorf, D., Woods, W. G., Ramsay, N. K. C. and Kersey, J. H. (1988). Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood, 72, 1512–1517.
  • Keating, S., Suciu, S., deWitte, T., Mandelli, F., Willemze, R., Resegotti, L., Broccia, G., Thaler, J., Labar, B., Damasio, E., Bizzi, B., Rotoli, B., Vekhoff, A., Muus, P., Petti, M. C., Dardenne, M., Solbu, G., Vegna, M. L. and Zittoun, R. A. (1996). Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GINE-MA AML 8A trial. Bone Marrow Transplant., 17, 993–1001.
  • Pawelec, G. (1994). Immune surveillance of leukemia: rationale for immunotherapy? Hematol. Rev., 8, 123–147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.